Last reviewed · How we verify
Sorafenib with Low-dose FP
Sorafenib is a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, combined with low-dose fluoropyrimidine (FP) chemotherapy to enhance anti-tumor effects.
Sorafenib is a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, combined with low-dose fluoropyrimidine (FP) chemotherapy to enhance anti-tumor effects. Used for Hepatocellular carcinoma (Phase 3 investigation).
At a glance
| Generic name | Sorafenib with Low-dose FP |
|---|---|
| Also known as | Nexavar, Low-dose FP |
| Sponsor | Ministry of Health, Labour and Welfare, Japan |
| Drug class | Multi-kinase inhibitor + chemotherapy combination |
| Target | RAF kinase, VEGFR, PDGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Sorafenib inhibits multiple receptor tyrosine kinases (RAF, VEGFR, PDGFR) involved in tumor growth and blood vessel formation. The addition of low-dose fluoropyrimidine chemotherapy provides complementary cytotoxic activity. This combination approach aims to improve efficacy over sorafenib monotherapy in hepatocellular carcinoma and potentially other solid tumors.
Approved indications
- Hepatocellular carcinoma (Phase 3 investigation)
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Fatigue
- Nausea/vomiting
- Myelosuppression
Key clinical trials
- Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC (PHASE3)
- Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorafenib with Low-dose FP CI brief — competitive landscape report
- Sorafenib with Low-dose FP updates RSS · CI watch RSS
- Ministry of Health, Labour and Welfare, Japan portfolio CI